Examination of the effects of varenicline, bupropion, lorcaserin, or naltrexone on responding for conditioned reinforcement in nicotine-exposed rats

Behavioural Pharmacology

Volumn 25, Issue 8, 2014, Pages 775-783

  Guy, Elizabeth G ^a,c   Fisher, Daniel C ^c   Higgins, Guy A ^b,d   Fletcher, Paul J ^a,c  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^d InterVivo Solutions Inc   (Canada)

Author keywords

Bupropion; Conditioned reinforcement; Lorcaserin; Naltrexone; Nicotine; Rat; Varenicline

Indexed keywords

AMFEBUTAMONE; LORCASERIN; NALTREXONE; NICOTINE; VARENICLINE; WATER; BENZAZEPINE DERIVATIVE; CHOLINERGIC RECEPTOR STIMULATING AGENT; NARCOTIC ANTAGONIST; QUINOXALINE DERIVATIVE;

ANIMAL EXPERIMENT; ARTICLE; CONDITIONING; CONTROLLED STUDY; DOSE RESPONSE; DRUG APPROVAL; DRUG MECHANISM; ENVIRONMENTAL EXPOSURE; FOOD AND DRUG ADMINISTRATION; INSTRUMENTAL CONDITIONING; MALE; NONHUMAN; RAT; REINFORCEMENT; ANIMAL; DRUG EFFECTS; DRUG INTERACTION; LONG EVANS RAT;

ANIMALS; BENZAZEPINES; BUPROPION; CHOLINERGIC AGENTS; CONDITIONING, OPERANT; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; MALE; NALTREXONE; NARCOTIC ANTAGONISTS; NICOTINE; QUINOXALINES; RATS; RATS, LONG-EVANS; REINFORCEMENT (PSYCHOLOGY);

EID: 84928122675     PISSN: 09558810     EISSN: 14735849     Source Type: Journal    
DOI: 10.1097/FBP.0000000000000092     Document Type: Article

References (79)

1. Anggadiredja K, Sakimura K, Hiranita T, Yamamoto T (2004). Naltrexone attenuates cue- but not drug-induced methamphetamine seeking: a possible mechanism for the dissociation of primary and secondary reward. Brain Res 1021:272-276.
2. Balfour DJ, Wright AE, Benwell ME, Birrell CE (2000). The putative role of extrasynaptic mesolimbic dopamine in the neurobiology of nicotine dependence. Behav Brain Res 113:73-83.
3. Beninger RJ, Hanson DR, Phillips AG (1980). The effects of pipradrol on the acquisition of responding with conditioned reinforcement: a role for sensory preconditioning. Psychopharmacology (Berl) 69:235-242.
4. Berridge KC (1996). Food reward: brain substrates of wanting and liking. Neurosci Biobehav Rev 20:1-25.
5. Berridge KC, Robinson TE (1998). What is the role of dopamine in reward: hedonic impact, reward learning, or incentive salience? Brain Res Brain Res Rev 28:309-369.
6. Berthoud HR, Morrison C (2008). The brain, appetite, and obesity. Annu Rev Psychol 59:55-92.
7. Brunzell DH, Chang JR, Schneider B, Olausson P, Taylor JR, Picciotto MR (2006). beta2-Subunit-containing nicotinic acetylcholine receptors are involved in nicotine-induced increases in conditioned reinforcement but not progressive ratio responding for food in C57BL/6 mice. Psychopharmacology (Berl) 184:328-338.
8. Brody AL, Mandelkern MA, Lee G, Smith E, Sadeghi M, Saxena S, et al. (2004). Attenuation of cue-induced cigarette craving and anterior cingulate cortex activation in bupropion-treated smokers: a preliminary study. Psychiatry Res 130:269-281.
9. Caggiula AR, Donny EC, White AR, Chaudhri N, Booth S, Gharib MA, et al. (2001). Cue dependency of nicotine self-administration and smoking. Pharmacol Biochem Behav 70:515-530.
10. CDC (2008). CDC Smoking-attributable mortality, years of potential life lost, and productivity losses-United States, 2000-2004. MMWR Morb Mortal Wkly Rep 57:1226-1228.
11. Chiamulera C (2005). Cue reactivity in nicotine and tobacco dependence: a 'multiple-action' model of nicotine as a primary reinforcement and as an enhancer of the effects of smoking-associated stimuli. Brain Res Brain Res Rev 48:74-97.
12. Ciccocioppo R, Martin-Fardon R, Weiss F (2002). Effect of selective blockade of mu(1) or delta opioid receptors on reinstatement of alcohol-seeking behavior by drug-associated stimuli in rats. Neuropsychopharmacology 27:391-399.
13. Corrigall WA, Coen KM (1991). Selective dopamine antagonists reduce nicotine self-administration. Psychopharmacology (Berl) 104:171-176.
14. Corrigall WA, Franklin KB, Coen KM, Clarke PB (1992). The mesolimbic dopaminergic system is implicated in the reinforcing effects of nicotine. Psychopharmacology (Berl) 107:285-289.
15. Cousins MS, Stamat HM, de Wit H (2001). Acute doses of D-amphetamine and bupropion increase cigarette smoking. Psychopharmacology (Berl) 157:243-253.
16. Cryan JF, Bruijnzeel AW, Skjei KL, Markou A (2003). Bupropion enhances brain reward function and reverses the affective and somatic aspects of nicotine withdrawal in the rat. Psychopharmacology (Berl) 168:347-358.
17. Cunningham ST, Kelley AE (1992). Opiate infusion into nucleus accumbens: contrasting effects on motor activity and responding for conditioned reward. Brain Res 588:104-114.
18. David S, Lancaster T, Stead L, Evins A (2009). Opioid antagonists for smoking cessation. Cochrane Database Syst Rev CD003086.
19. Di Chiara G, Imperato A (1988). Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proc Natl Acad Sci USA 85:5274-5278.
20. Epping-Jordan MP, Watkins SS, Koob GF, Markou A (1998). Dramatic decreases in brain reward function during nicotine withdrawal. Nature 393:76-79.
21. Everitt BJ, Robbins TW (2005). Neural systems of reinforcement for drug addiction: from actions to habits to compulsion. Nat Neurosci 8:1481-1489.
22. Ferguson SG, Shiffman S (2009). The relevance and treatment of cue-induced cravings in tobacco dependence. J Subst Abuse Treat 36:235-243.
23. Fletcher PJ (1996). Injection of 5-HT into the nucleus accumbens reduces the effects of D-amphetamine on responding for conditioned reward. Psychopharmacology (Berl) 126:62-69.
24. Fletcher PJ, Korth KM, Robinson SR, Baker GB (2002). Multiple 5-HT receptors are involved in the effects of acute MDMA treatment: studies on locomotor activity and responding for conditioned reinforcement. Psychopharmacology (Berl) 162:282-291.
25. Fletcher PJ, Rizos Z, Noble K, Soko AD, Silenieks LB, Lê AD, Higgins GA (2012). Effects of the 5-HT2C receptor agonist Ro60-0175 and the 5-HT2A receptor antagonist M100907 on nicotine self-administration and reinstatement. Neuropharmacology 62:2288-2298.
26. Franklin T, Wang Z, Suh JJ, Hazan R, Cruz J, Li Y, et al. (2011). Effects of varenicline on smoking cue-triggered neural and craving responses. Arch Gen Psychiatry 68:516-526.
27. George TP, O'Malley SS (2004). Current pharmacological treatments for nicotine dependence. Trends Pharmacol Sci 25:42-48.
28. Glick SD, Maisonneuve IM, Kitchen BA (2002). Modulation of nicotine selfadministration in rats by combination therapy with agents blocking alpha 3 beta 4 nicotinic receptors. Eur J Pharmacol 448:185-191.
29. Grottick AJ, Trube G, Corrigall WA, Huwyler J, Malherbe P, Wyler R, Higgins GA (2000). Evidence that nicotinic alpha(7) receptors are not involved in the hyperlocomotor and rewarding effects of nicotine. J Pharmacol Exp Ther 294:1112-1119.
30. Guy EG, Fletcher PJ (2013). Nicotine-induced enhancement of responding for conditioned reinforcement in rats: role of prior nicotine exposure and a4ß2 nicotinic receptors. Psychopharmacology (Berl) 225:429-440.
31. Higgins GA, Fletcher PJ (2003). Serotonin and drug reward: focus on 5-HT2C receptors. Eur J Pharmacol 480:151-162.
32. Higgins GA, Silenieks LB, Rossmann A, Rizos Z, Noble K, Soko AD, Fletcher PJ (2012). The 5-HT2C receptor agonist lorcaserin reduces nicotine selfadministration, discrimination, and reinstatement: relationship to feeding behavior and impulse control. Neuropsychopharmacology 37:1177-1191.
33. Higgins GA, Silenieks LB, Lau W, De Lannoy IA, Lee DK, Coen K, et al. (2013a). Evaluation of chemically diverse 5-HT2C receptor agonists on behaviours motivated by food and nicotine and on side effect profiles. Psychopharmacology (Berl) 226:475-490.
34. Higgins GA, Sellers EM, Fletcher PJ (2013b). From obesity to substance abuse: therapeutic opportunities for 5-HT2C receptor agonists. Trends Pharmacol Sci 34:560-570.
35. Hildebrand BE, Nomikos GG, Hertel P, Schilström B, Svensson TH (1998). Reduced dopamine output in the nucleus accumbens but not in the medial prefrontal cortex in rats displaying a mecamylamine-precipitated nicotine withdrawal syndrome. Brain Res 779:214-225.
36. Hughes JR, Stead LF, Hartmann-Boyce J, Cahill K, Lancaster T (2014). Antidepressants for smoking cessation. Cochrane Database Syst Rev 1: CD000031.
37. Hurt RD, Sachs DP, Glover ED, Offord KP, Johnston JA, Dale LC, et al. (1997). A comparison of sustained-release bupropion and placebo for smoking cessation. N Engl J Med 337:1195-1202.
38. Janes AC, Pizzagalli DA, Richardt S, deB Frederick B, Chuzi S, Pachas G, et al. (2010). Brain reactivity to smoking cues prior to smoking cessation predicts ability to maintain tobacco abstinence. Biol Psychiatry 67:722-729.
39. Kelley AE, Bakshi VP, Haber SN, Steininger TL, Will MJ, Zhang M (2002). Opioid modulation of taste hedonics within the ventral striatum. Physiol Behav 76:365-377.
40. LeSage MG, Burroughs D, Dufek M, Keyler DE, Pentel PR (2004). Reinstatement of nicotine self-administration in rats by presentation of nicotine-paired stimuli, but not nicotine priming. Pharmacol Biochem Behav 79:507-513.
41. Levin ED, Johnson JE, Slade S, Wells C, Cauley M, Petro A, Rose JE (2011). Lorcaserin, a 5-HT2C agonist, decreases nicotine self-administration in female rats. J Pharmacol Exp Ther 338:890-896.
42. Levin ME, Weaver MT, Palmatier MI, Caggiula AR, Sved AF, Donny EC (2012). Varenicline dose dependently enhances responding for nonpharmacological reinforcers and attenuates the reinforcement-enhancing effects of nicotine. Nicotine Tob Res 14:299-305.
43. Liu X, Palmatier MI, Caggiula AR, Sved AF, Donny EC, Gharib M, Booth S (2009). Naltrexone attenuation of conditioned but not primary reinforcement of nicotine in rats. Psychopharmacology (Berl) 202:589-598.
44. Mackintosh NJ (1974). The psychology of animal learning. New York: Academic Press.
45. McGranahan TM, Patzlaff NE, Grady SR, Heinemann SF, Booker TK (2011). a4ß2 nicotinic acetylcholine receptors on dopaminergic neurons mediate nicotine reward and anxiety relief. J Neurosci 31:10891-10902.
46. Mihalak KB, Carroll FI, Luetje CW (2006). Varenicline is a partial agonist at alpha4beta2 and a full agonist at alpha7 neuronal nicotinic receptors. Mol Pharmacol 70:801-805.
47. Neisewander JL, Acosta JI (2007). Stimulation of 5-HT2C receptors attenuates cue and cocaine-primed reinstatement of cocaine-seeking behavior in rats. Behav Pharmacol 18:791-800.
48. Nomikos GG, Damsma G, Wenkstern D, Fibiger HC (1992). Effects of chronic bupropion on interstitial concentrations of dopamine in rat nucleus accumbens and striatum. Neuropsychopharmacology 7:7-14.
49. O'Connor EC, Parker D, Rollema H, Mead AN (2010). The alpha4beta2 nicotinic acetylcholine-receptor partial agonist varenicline inhibits both nicotine selfadministration following repeated dosing and reinstatement of nicotine seeking in rats. Psychopharmacology (Berl) 208:365-376.
50. Olausson P, Jentsch JD, Taylor JR (2004). Nicotine enhances responding with conditioned reinforcement. Psychopharmacology (Berl) 171:173-178.
51. Ortells MO, Barrantes GE (2010). Tobacco addiction: a biochemical model of nicotine dependence. Med Hypotheses 74:884-894.
52. Palmatier MI, Levin ME, Mays KL, Donny EC, Caggiula AR, Sved AF (2009). Bupropion and nicotine enhance responding for nondrug reinforcers via dissociable pharmacological mechanisms in rats. Psychopharmacology (Berl) 207:381-390.
53. Parkinson JA, Olmstead MC, Burns LH, Robbins TW, Everitt BJ (1999). Dissociation in effects of lesions of the nucleus accumbens core and shell on appetitive Pavlovian approach behavior and the potentiation of conditioned reinforcement and locomotor activity by D-amphetamine. J Neurosci 19:2401-2411.
54. Picciotto MR, Zoli M, Rimondini R, Léna C, Marubio LM, Pich EM, et al. (1998). Acetylcholine receptors containing the beta2 subunit are involved in the reinforcing properties of nicotine. Nature 391:173-177.
55. Polosa R, Benowitz NL (2011). Treatment of nicotine addiction: present therapeutic options and pipeline developments. Trends Pharmacol Sci 32:281-289.
56. Rauhut AS, Neugebauer N, Dwoskin LP, Bardo MT (2003). Effect of bupropion on nicotine self-administration in rats. Psychopharmacology (Berl) 169:1-9.
57. Rauhut AS, Dwoskin LP, Bardo MT (2005). Tolerance does not develop to the decrease in nicotine self-administration produced by repeated bupropion administration. Nicotine Tob Res 7:901-907.
58. Robbins TW (1975). The potentiation of conditioned reinforcement by psychomotor stimulant drugs. A test of Hill's hypothesis. Psychopharmacologia 45:103-114.
59. Robbins TW (1978). The acquisition of responding with conditioned reinforcement: effects of pipradrol, methylphenidate, D-amphetamine, and nomifensine. Psychopharmacology (Berl) 58:79-87.
60. Rollema H, Chambers LK, Coe JW, Glowa J, Hurst RS, Lebel LA, et al. (2007a). Pharmacological profile of the alpha4beta2 nicotinic acetylcholine receptor partial agonist varenicline, an effective smoking cessation aid. Neuropharmacology 52:985-994.
61. Rollema H, Coe JW, Chambers LK, Hurst RS, Stahl SM, Williams KE (2007b). Rationale, pharmacology and clinical efficacy of partial agonists of alpha4-beta2 nACh receptors for smoking cessation. Trends Pharmacol Sci 28:316-325.
62. Rose JE, Behm FM, Westman EC, Johnson M (2000). Dissociating nicotine and nonnicotine components of cigarette smoking. Pharmacol Biochem Behav 67:71-81.
63. Saunders BT, Robinson TE (2013). Individual variation in resisting temptation: implications for addiction. Neurosci Biobehav Rev 37 (Pt A):1955-1975.
64. Shaham Y, Adamson LK, Grocki S, Corrigall WA (1997). Reinstatement and spontaneous recovery of nicotine seeking in rats. Psychopharmacology (Berl) 130:396-403.
65. Shoaib M, Sidhpura N, Shafait S (2003). Investigating the actions of bupropion on dependence-related effects of nicotine in rats. Psychopharmacology (Berl) 165:405-412.
66. Spanagel R, Weiss F (1999). The dopamine hypothesis of reward: past and current status. Trends Neurosci 22:521-527.
67. Spanagel R, Herz A, Shippenberg TS (1990). The effects of opioid peptides on dopamine release in the nucleus accumbens: an in vivo microdialysis study. J Neurochem 55:1734-1740.
68. Spiller K, Xi ZX, Li X, Ashby CR Jr, Callahan PM, Tehim A, Gardner EL (2009). Varenicline attenuates nicotine-enhanced brain-stimulation reward by activation of alpha4beta2 nicotinic receptors in rats. Neuropharmacology 57:60-66.
69. Stolerman IP, Jarvis MJ (1995). The scientific case that nicotine is addictive. Psychopharmacology (Berl) 117:2-10.
70. Taylor JR, Robbins TW (1984). Enhanced behavioural control by conditioned reinforcers following microinjections of d-amphetamine into the nucleus accumbens. Psychopharmacology (Berl) 84:405-412.
71. Taylor JR, Robbins TW (1986). 6-Hydroxydopamine lesions of the nucleus accumbens, but not of the caudate nucleus, attenuate enhanced responding with reward-related stimuli produced by intra-accumbens D-amphetamine. Psychopharmacology (Berl) 90:390-397.
72. Threlfell S, Lalic T, Platt NJ, Jennings KA, Deisseroth K, Cragg SJ (2012). Striatal dopamine release is triggered by synchronized activity in cholinergic interneurons. Neuron 75:58-64.
73. Tobey KM, Walentiny DM, Wiley JL, Carroll FI, Damaj MI, Azar MR, et al. (2012). Effects of the specific a4ß2 nAChR antagonist, 2-fluoro-3-(4-nitrophenyl) deschloroepibatidine, on nicotine reward-related behaviors in rats and mice. Psychopharmacology (Berl) 223:159-168.
74. Vezina P, McGehee DS, GreenWN (2007). Exposure to nicotine and sensitization of nicotine-induced behaviors. Prog Neuropsychopharmacol Biol Psychiatry 31:1625-1638.
75. Warner C, Shoaib M (2005). How does bupropion work as a smoking cessation aid? Addict Biol 10:219-231.
76. Weaver MT, Sweitzer M, Coddington S, Sheppard J, Verdecchia N, Caggiula AR, et al. (2012). Precipitated withdrawal from nicotine reduces reinforcing effects of a visual stimulus for rats. Nicotine Tob Res 14:824-832.
77. Williamson DF, Madans J, Anda RF, Kleinman JC, Giovino GA, Byers T (1991). Smoking cessation and severity of weight gain in a national cohort. N Engl J Med 324:739-746.
78. Zaniewska M, McCreary AC, Filip M (2009). Interactions of serotonin (5-HT)2 receptor-targeting ligands and nicotine: locomotor activity studies in rats. Synapse 63:653-661.
79. Zernig G, De Wit H, Telser S, Nienhusmeier M, Wakonigg G, Sturm K, et al. (2004). Subjective effects of slow-release bupropion versus caffeine as determined in a quasi-naturalistic setting. Pharmacology 70:206-215.